Remdesivir News and Research

RSS

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. The study results are posted to the medRxiv* preprint server.

6 Jan 2022

Statistical analysis reveals less severe COVID-19 outcome due to Omicron variant

A new study demonstrated that in the US, the COVID-19 cases arising after the emergence of the SARS-CoV-2 Omicron variant showed reduced severity of infection than in the cases recorded in previous time points (during the Delta variant outbreak).

5 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

A new study shows that the optimization of nitazoxanide formulations may allow the review of the potential use of the drug for the treatment of SARS-CoV-2 infection.

22 Dec 2021

New oral pill for COVID-19 home treatment

As cases and hospitalizations continue to rise in many countries, new treatments are being sought to arrest the progression of the disease, preventing severe illness and death or disability. One such is the small molecule molnupiravir, the focus of a new research paper.

20 Dec 2021

SARS-CoV-2 VOCs dependent on IFITM2 for efficient infection establishment

Researchers demonstrate that the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 require endogenous IFITM2 expression for efficient replication.

15 Dec 2021

Impact of exogenous antibody therapy by convalescent plasma against SARS-CoV-2

Researches have been investigating the possibility of using convalescent plasma to help patients recover from COVID-19.

15 Dec 2021

The antiviral potential of 4′-fluorouridine as an oral treatment against RSV and SARS-CoV-2

New research reports 4’-Fluorouridine (4′-FlU) as an oral antiviral against RSV and SARS-CoV-2.

7 Dec 2021

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

In new studies, researchers concluded that licorice triterpenoids could be candidates for anti-SARS-CoV-2 drug developments.

2 Dec 2021

An antiviral regimen based on biomimetic polymers for COVID-19

In a new study published on the bioRxiv* preprint server, scientists proposed the aforementioned mechanism of action (MOA) and have validated it using electron photomicrographs of murine cytomegalovirus (MCMV), which were incubated with a nanoviricide.

30 Nov 2021

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

A new paper deals with the identification of an antiviral compound that could help in developing additional drugs to help fight COVID-19.

30 Nov 2021

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

In a new study, published on the bioRxiv* preprint server, scientists aimed to determine the reaction of the molnupiravir parent drug (NHC) to different SARS-CoV-2 Variants of Concern (VoCs). They also sought to establish the therapeutic window in a human lung cell model.

29 Nov 2021

Study finds atazanavir inhibits main SARS-CoV-2 protease

Research shows that ATV has different antiviral activity compared to PAXLOVID™, encouraging further research.

29 Nov 2021

Complex RNA structures could have untapped therapeutic potential in the fight against COVID-19

To the untrained eye, the loops, kinks and folds in the single strand of RNA that makes up the coronavirus genome look like a jumble of spaghetti or tangled yarn. But to researchers like Amanda Hargrove, a chemistry professor at Duke University, the complex shapes that RNA takes on as it folds upon itself could have untapped therapeutic potential in the fight against COVID-19.

26 Nov 2021

Remdesivir News and Research

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

Statistical analysis reveals less severe COVID-19 outcome due to Omicron variant

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

New oral pill for COVID-19 home treatment

SARS-CoV-2 VOCs dependent on IFITM2 for efficient infection establishment

Impact of exogenous antibody therapy by convalescent plasma against SARS-CoV-2

The antiviral potential of 4′-fluorouridine as an oral treatment against RSV and SARS-CoV-2

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

An antiviral regimen based on biomimetic polymers for COVID-19

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

Study finds atazanavir inhibits main SARS-CoV-2 protease

Complex RNA structures could have untapped therapeutic potential in the fight against COVID-19

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

An increase in the half-life of remdesivir for COVID-19 treatment

IFITM proteins are important replication cofactors for SARS-CoV-2, including Delta variant

Modeling the role of antivirals in suppressing the COVID-19 pandemic

Could drugs derived from microalgae be effective against COVID-19?

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News